Effects of Unfractionated and Low Molecular Weight Heparins on Platelet Thromboxane Biosynthesis “In Vivo”

Summary

Several “in vitro” and “in vivo” studies indicate that heparin administration may affect platelet function. In this study we investigated the effects of prophylactic heparin on thromboxane (Tx)A₂ biosynthesis “in vivo”, as assessed by the urinary excretion of major enzymatic metabolites 11-dehydro-TxB₂ and 2,3-dinor-TxB₂. Twenty-four patients who were candidates for cholecystectomy because of uncomplicated lithiasis were randomly assigned to receive placebo, unfractionated heparin, low molecular weight heparin or unfractionaed heparin plus 100 mg aspirin. Measurements of daily excretion of Tx metabolites were performed before and during the treatment. In the groups assigned to placebo and to low molecular weight heparin there was no statistically significant modification of Tx metabolite excretion while patients receiving unfractionated heparin had a significant increase of both metabolites (11-dehydro-TxB₂: 3844 ± 1388 vs 2092 ±777, p <0.05; 2,3-dinor-TxB₂: 2737 ± 808 vs 1535 ± 771 pg/mg creatinine, p <0.05). In patients randomized to receive low-dose aspirin plus unfractionated heparin the excretion of the two metabolites was largely suppressed thus suggesting that platelets are the primary source of enhanced thromboxane biosynthesis associated with heparin administration. These data indicate that unfractionated heparin causes platelet activation “in vivo” and suggest that the use of low molecular weight heparin may avoid this complication.

• References

• 1 Hirsh JHeparin. N Engl J Med 1991; 324: 1565-1574
• 2 Ofosu FA, Danishefsly I, Hirsh J. Heparin and related polysaccharides: structure and activities. Ann NY Acad Sci 1989; 556: 1-501
• 3 Lane D, Adams L. Non-anticoagulant uses of heparin. N Engl J Med 1993; 329: 129-130
• 4 Vermylen JG. Effect of heparin and low molecular weight heparins on platelets. Sem Thromb Hemost 1993; 19: 20-21
• 5 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Progr Hemost Thromb 1991; 10: 1-34
• 6 Roberts LJII, Sweeyman BJ, Oates JA. Metabolism of thromboxane B₂ in man. Identification of twenty urinary metabolites. J Biol Chem 1981; 256: 8384-8393
• 7 Ciabattoni G, Pugliese F, Davì G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B₂ to urinary 11-dehydro-thrombo-xane B₂ in man. Biochim Biophys Acta 1989; 992: 66-70
• 8 Landolfi R, Ciabattoni G, Patrignani P, Castellana MA, Pogliani E, Bizzi B, Patrono C. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80: 1965-1971
• 9 Ciabattoni G, Maclouf J, Catella F, FitzGerald GA, Patrono C. Radioimmunoassay of 11-dehydro-thromboxane B₂ in human plasma and urine. Biochim Biophys Acta 1987; 918: 293-297
• 10 Patrono C, Ciabattoni G, Remuzzi G, Gotti E, Bombardieri S, Di Munno O, Tartarelli G, Cinotti GA, Simonetti BM, Pierucci A. Functional significance in renal prostacyclin and thromboxane A₂ production in patients with systemic lupus erythematosus. J Clin Invest 1985; 76: 1011-1018
• 11 Barzu T, Molho P, Tobelem G, Petita M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985; 845: 196-203
• 12 Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res 1978; 12: 773-782
• 13 Hoover RL, Rosenberg RD, Haering W, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies. Circ Res 1980; 47: 578-783
• 14 Castellot JJJr, Wright TCJr, Karnovsky MJ. Regulation of vascular smooth muscle cell growth by heparin. In: Sem Thromb Hemost. Stern DM, Nawroth PP. eds Thieme, Inc; New York: 1987. 13 489-503
• 15 Horne McDonald III, Chao E. Heparin binding to resting and activated platelets. Blood 1989; 74: 238-243
• 16 Messmore HLJr, Griffin Beth, Fareed J, Coyne E, Seghatchian J. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. In: Heparin and related polysaccharides: structure and activities. Ofosu FA, Danishefsky I, Hirsh J. eds Ann NY Acad Sci. 1989. 556 217-232
• 17 John LC, Rees GM, Kovacs IB. Inhibition of platelet function by heparin. J Thorac Cardiovasc Surg 1993; 105: 816-822
• 18 Heiden D, Mielke CH, Rodvien R. Impairment by heparin of primary haemostasis and platelet (C14) 5-hydroxytryptamine release. Br J Haematol 1977; 36: 427-436
• 19 Kelton JG. Heparin-induced thrombocytopenia. Haemostasis 1986; 16: 173-186
• 20 Eika C. The platelet aggregating effect of eight commercial heparins. Scand J Haematol 1972; 9: 480-482
• 21 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effects of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
• 22 Barradas MA, Mikhailidis DP, Epemolu O, Jeremy JY, Fonseca V, Dan-dona P. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222). Br J Haematol 1987; 67: 451-457
• 23 Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG anti-body that induces thromboxane synthesis and platelet aggregation. Lancet 1982; 2: 1246-1249
• 24 Chong BH, Castaldi PA. Platelet proaggregating effect of heparin: Possible mechanism for non-immune heparin-associated thrombocytopenia. Aust N ZJMed 1986; 16: 715-716
• 25 Chong BH, Berndt MC. Heparin-induced thrombocytopenia. Blut 1989; 58: 53-57
• 26 Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Pa-trono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-1774
• 27 Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987; 76: 6-14
• 28 Lewy RI, Wiener L, Smith JB, Walinsky P, Silver MJ. Intravenous heparin initiates in-vivo synthesis and release of thromboxane in angina pectoris (letter). Lancet 1979; 2: 97
• 29 FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-1176
• 30 Fabris F, Fussi F, Casonato A, Visentin L, Randi M, Smith MR, Girolami A. Normal and low molecular weight heparins: interaction with human platelets. Eur J Clin Invest 1983; 13: 135-139
• 31 Chen J, Sylven C. Heparin potentiation of collagen-induced platelet aggregations is related to the GpIIb-IIIa receptor and not to the Gplb receptor, as tested by whole blood aggregometry. Thromb Res 1992; 66: 111-120
• 32 Heinrich D, Görg T. Fibrinogen-binding to platelets is augmented by unfractionated heparin. In: Fibrinogen and its derivatives. Mueller-Berghaus G, Scheffers-Borchel U, Selmayr E, Henschen A. eds Excerpta Medica; Amsterdam - New York - Oxford: 1986: 131-134
• 33 Soria C, Soria J, Thomaidis A, Dunn F, Tobelem G, Caen JP. Comparison between the effect of heparin and low molecular weight heparins on the exposure of fibrinogen receptors on the platelet surface. In: Fibrinogen and its derivatives. Mueller-Berghaus G, Scheffers-Borchel U, Selmayr E, Henschen A. eds Excerpta Medica; Amsterdam - New York - Oxford: 1986: 13
• 34 Mirshahi MC, Soria J, Neuhart E, Steg PG, Jaab P, Combe S, Soria C. Effect of heparin and enoxaparin on platelet interaction with fibrin clots. Thromb Res 1992; 65: 187-192
• 35 Hirsh J, Levine M. Low molecular weight heparin. Blood 1992; 79: 1-17